BIOSYNEX Diagnostics is a prominent European manufacturer and provider of rapid membrane tests in the in-vitro diagnostic market. Founded in 2005 with headquarters in France, BIOSYNEX is committed to understanding the needs and expectations of its customers and partners. The company's Research and Development laboratories and state-of-the-art manufacturing facilities enable them to identify new applications in rapid testing, develop innovative products, and provide high-quality services. Their goal is to offer innovative diagnostic tests to aid physicians in making fast and accurate medical decisions, ultimately saving lives. BIOSYNEX received a Post-IPO Equity investment on 26 November 2021. With a focus on Biotechnology, Manufacturing, and Marketing, BIOSYNEX remains dedicated to driving innovation in biotherapies.
BIOSYNEX Diagnostics
Innovation for Biotherapies
France
71 employees
Post-IPO Equity
Total: $18.90M
Biotechnology, Manufacturing +1
General Information
France
BounceWatch is an independent company data service, not affiliated with BIOSYNEX Diagnostics. To contact BIOSYNEX Diagnostics, visit theradiag.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does BIOSYNEX Diagnostics compare?
A PDF of BIOSYNEX Diagnostics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting BIOSYNEX Diagnostics soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
France Market
Biotechnology
About BIOSYNEX Diagnostics
Business keywords: In-vitro diagnostics, Rapid membrane tests, Biological diagnostic tools, Autoimmune diseases diagnostics, Allergies diagnostics, Infectious diseases diagnostics, Research and Development, Innovative products, Diagnostic testing, Biotechnologies, Theranostic, Medical decision support, Biotherapies, France-based company
Services & Products
Target Customers
Funding Rounds & Investors (4)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post IPO Equity | Undisclosed | - |
|
26 Nov 2021 |
| Series C | €5.00M | 6 |
|
02 Jun 2005 |
| Series B | €9.30M | 4 |
|
01 May 2003 |
| Series A | €4.60M | 4 |
|
01 Jan 2000 |
BIOSYNEX Diagnostics Alternatives & Competitors
View All Alternatives
Advanced molecular analysis technologies to harness the power of the microbiota.
We help make the world a healthier place
Aidian develops, manufactures and markets diagnostic tests and test solutions.
FAQ About BIOSYNEX Diagnostics
Source: BounceWatch company record for BIOSYNEX Diagnostics, https://bouncewatch.com/company/biosynex-diagnostics, updated 7 June 2025. When citing, please name BounceWatch and link this page.
